Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Sebti

Showing results (11-20 of 102) with videos related to

Pageof 11
Sort By:
Methods in Enzymology|October 19, 2000
Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitorsS M Sebti, A D Hamilton
Mutation Research|February 1, 1984
Rat liver homogenate (S9)-mediated binding of benzo[alpha]pyrene to DNA in V79 cells, V79 cell nuclei and aqueous solutionS M Sebti, W M Baird
Pharmacology & Therapeutics|January 1, 1988
Metabolic inactivation of bleomycin analogs by bleomycin hydrolaseS M Sebti, J S Lazo
Oncogene|January 30, 2007
A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathwayA E Carie, S M Sebti
Oncogene|January 23, 1997
Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicityT F McGuire, S M Sebti
Oncogene|June 28, 2001
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studiesS M Sebti, A D Hamilton
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
BleomycinJ S Lazo, S M Sebti
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
BleomycinsJ S Lazo, S M Sebti
Biopolymers|January 1, 1997
Farnesyltransferase as a target for anticancer drug designY Qian, S M Sebti, A D Hamilton
The Journal of Biological Chemistry|October 25, 1993
Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptorT F McGuire, S J Corey, S M Sebti
Pageof 11

Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
Methods in Enzymology|October 19, 2000
Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitorsS M Sebti, A D Hamilton
Mutation Research|February 1, 1984
Rat liver homogenate (S9)-mediated binding of benzo[alpha]pyrene to DNA in V79 cells, V79 cell nuclei and aqueous solutionS M Sebti, W M Baird
Pharmacology & Therapeutics|January 1, 1988
Metabolic inactivation of bleomycin analogs by bleomycin hydrolaseS M Sebti, J S Lazo
Oncogene|January 30, 2007
A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathwayA E Carie, S M Sebti
Oncogene|January 23, 1997
Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicityT F McGuire, S M Sebti
Oncogene|June 28, 2001
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studiesS M Sebti, A D Hamilton
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1994
BleomycinJ S Lazo, S M Sebti
Cancer Chemotherapy and Biological Response Modifiers|January 1, 1992
BleomycinsJ S Lazo, S M Sebti
Biopolymers|January 1, 1997
Farnesyltransferase as a target for anticancer drug designY Qian, S M Sebti, A D Hamilton
The Journal of Biological Chemistry|October 25, 1993
Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptorT F McGuire, S J Corey, S M Sebti
Pageof 11